Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
ATLANTA, Sept. 06, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016 earnings conference call and webcast while it concludes discussions involving the accounting treatment for its recent sale of its Inavir® royalty rights to HealthCare Royalty Partners. Aviragen will announce the new time for its conference call and webcast in the next several days.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
